Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

At the OCT DACH conference, experts shared how EU laws, digitalisation, and more, are impacting trials in the DACH region and ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...